Clinical Trials in R/R Multiple Myeloma

By Joseph Mikhael, MD
Elisabet E. Manasanch, MD
A. Keith Stewart, MB ChB
Sikander Ailawadhi, MD

Dr Joseph Mikhael and expert panel discuss key efficacy and safety outcomes of pivotal clinical trials evaluating treatment regimens in patients with R/R multiple myeloma.

Related Videos
View All
Related Content

Updated MAIA Data Show D-Rd Maintains Survival Benefit Over Rd in Transplant-Ineligible, Newly Diagnosed Myeloma

January 29th 2023

Expert and Patient Perspectives on Comprehensive Multiple Myeloma Treatment

December 22nd 2022

KRd Improves PFS as Maintenance Therapy in Transplant-Eligible Multiple Myeloma

January 25th 2023

Mikhael and Cole Share Insights on Culturally Relevant Myeloma Care

October 27th 2022

Ide-cel Elicits Durable Responses in High-risk Myeloma After Inadequate ASCT Response

January 24th 2023

Daratumumab, Lenalidomide, Dexamethasone Improves OS in Relapsed/Refractory Multiple Myeloma

January 16th 2023

Updated MAIA Data Show D-Rd Maintains Survival Benefit Over Rd in Transplant-Ineligible, Newly Diagnosed Myeloma

January 29th 2023

Expert and Patient Perspectives on Comprehensive Multiple Myeloma Treatment

December 22nd 2022

KRd Improves PFS as Maintenance Therapy in Transplant-Eligible Multiple Myeloma

January 25th 2023

Mikhael and Cole Share Insights on Culturally Relevant Myeloma Care

October 27th 2022

Ide-cel Elicits Durable Responses in High-risk Myeloma After Inadequate ASCT Response

January 24th 2023

Daratumumab, Lenalidomide, Dexamethasone Improves OS in Relapsed/Refractory Multiple Myeloma

January 16th 2023

Updated MAIA Data Show D-Rd Maintains Survival Benefit Over Rd in Transplant-Ineligible, Newly Diagnosed Myeloma

January 29th 2023

Expert and Patient Perspectives on Comprehensive Multiple Myeloma Treatment

December 22nd 2022

KRd Improves PFS as Maintenance Therapy in Transplant-Eligible Multiple Myeloma

January 25th 2023

Mikhael and Cole Share Insights on Culturally Relevant Myeloma Care

October 27th 2022

Ide-cel Elicits Durable Responses in High-risk Myeloma After Inadequate ASCT Response

January 24th 2023

Daratumumab, Lenalidomide, Dexamethasone Improves OS in Relapsed/Refractory Multiple Myeloma

January 16th 2023
Advertise
About OncLive
Editorial Board
CancerNetwork.com
CGTlive.com
CureToday.com
OncNursingNews.com
TargetedOnc.com
Contact Us
Privacy
Terms & Conditions
Do Not Sell My Information
Contact Info

2 Clarke Drive
Cranbury, NJ 08512

609-716-7777

© 2023 MJH Life Sciences

All rights reserved.
Home
About Us
News
Contact